DOP2009000232A - Metanoisoindoles y dionas de éstos como agentes anti-psicóticos. - Google Patents
Metanoisoindoles y dionas de éstos como agentes anti-psicóticos.Info
- Publication number
- DOP2009000232A DOP2009000232A DO2009000232A DO2009000232A DOP2009000232A DO P2009000232 A DOP2009000232 A DO P2009000232A DO 2009000232 A DO2009000232 A DO 2009000232A DO 2009000232 A DO2009000232 A DO 2009000232A DO P2009000232 A DOP2009000232 A DO P2009000232A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- metanoisoindoles
- dionas
- psychotic agents
- antisychotics
- ht2a
- Prior art date
Links
- 239000000164 antipsychotic agent Substances 0.000 title 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 abstract 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 230000005062 synaptic transmission Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
La presente invención se refiere a agentes terapéuticos de la Fórmula (I), que son antisicóticos atípicos y que son útiles en el tratamiento de trastornos neurológicos y psiquiátricos asociados con la disfunción de la neurotransmisión de dopamina D2 y serotonina 5-HT2A, donde R1 es C1-6 alquilo, el cual es no sustituido o sustituido con 1-6 fluoro, donde R1 y el grupo hidroxilo del anillo estás unidos al mismo átomo de carbono; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92175907P | 2007-04-04 | 2007-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2009000232A true DOP2009000232A (es) | 2016-11-15 |
Family
ID=39540659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2009000232A DOP2009000232A (es) | 2007-04-04 | 2009-10-02 | Metanoisoindoles y dionas de éstos como agentes anti-psicóticos. |
Country Status (33)
Country | Link |
---|---|
US (3) | US8252799B2 (es) |
EP (1) | EP2144905B1 (es) |
JP (2) | JP5097265B2 (es) |
KR (1) | KR101562835B1 (es) |
CN (1) | CN101675046B (es) |
AU (1) | AU2008236705B2 (es) |
BR (1) | BRPI0809492A2 (es) |
CA (1) | CA2682494C (es) |
CO (1) | CO6300938A2 (es) |
CR (1) | CR11047A (es) |
CY (1) | CY1113649T1 (es) |
DK (1) | DK2144905T3 (es) |
DO (1) | DOP2009000232A (es) |
EC (1) | ECSP099674A (es) |
ES (1) | ES2398312T3 (es) |
GT (1) | GT200900258A (es) |
HK (1) | HK1134291A1 (es) |
HR (1) | HRP20130041T8 (es) |
IL (1) | IL201235A (es) |
MA (1) | MA31323B1 (es) |
MX (1) | MX2009010678A (es) |
MY (1) | MY153868A (es) |
NI (1) | NI200900175A (es) |
NZ (1) | NZ580167A (es) |
PL (1) | PL2144905T3 (es) |
PT (1) | PT2144905E (es) |
RS (1) | RS52661B (es) |
RU (1) | RU2468025C2 (es) |
SI (1) | SI2144905T1 (es) |
SV (1) | SV2009003380A (es) |
UA (1) | UA96015C2 (es) |
WO (1) | WO2008124030A1 (es) |
ZA (1) | ZA200906525B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000032987A (ja) * | 1998-07-16 | 2000-02-02 | Dai Ichi Seiyaku Co Ltd | Dna |
DE60327634D1 (de) | 2002-08-22 | 2009-06-25 | Dainippon Sumitomo Pharma Co | Mittel zur behandlung des integrationsdysfunktionssyndroms |
EP1637530A4 (en) | 2003-06-23 | 2009-04-01 | Dainippon Sumitomo Pharma Co | THERAPEUTIC AGENT FOR SENILE DEMENTIA |
EP1726952A4 (en) | 2004-02-20 | 2008-06-18 | Dainippon Sumitomo Pharma Co | METHOD FOR IN VIVO SCREENING OF A THERAPEUTIC FOR A MEMORY / LEARNING FUNCTION THROUGH SCHIZOPHRENIA |
ES2398312T3 (es) | 2007-04-04 | 2013-03-15 | Merck Sharp & Dohme Corp. | Agentes terapéuticos |
US20110124659A1 (en) * | 2009-11-17 | 2011-05-26 | Dainippon Sumitomo Pharma Co., Ltd. | Cycloalkane derivative |
US8258139B2 (en) | 2010-11-08 | 2012-09-04 | Dainippon Sumitomo Pharma Co., Ltd. | Method of treatment for mental disorders |
HUE065359T2 (hu) | 2011-03-18 | 2024-05-28 | Alkermes Pharma Ireland Ltd | Szorbitán-észtereket tartalmazó gyógyászati készítmények |
CA2867121C (en) * | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
WO2013142205A1 (en) | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
CA2867123C (en) | 2012-03-19 | 2021-02-16 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters |
US20130289019A1 (en) * | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
US9193685B2 (en) | 2012-09-19 | 2015-11-24 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
CN103207246B (zh) * | 2012-12-21 | 2017-10-10 | 北京万全德众医药生物技术有限公司 | 一种用液相色谱法分离测定鲁拉西酮及其光学异构体的方法 |
CN104140421B (zh) * | 2013-05-08 | 2017-04-05 | 上海医药工业研究院 | 苯并异噻唑类化合物及在制备抗精神***症药物中的应用 |
CN110368360A (zh) | 2014-03-20 | 2019-10-25 | 奥克梅斯制药爱尔兰有限公司 | 具有增加的注射速度的阿立哌唑制剂 |
PL3344273T3 (pl) * | 2015-08-31 | 2020-06-01 | Nutramax Laboratories, Inc. | Kompozycje zawierające magnolię, korkowiec, teaninę i/lub białko serwatkowe |
CN112423754A (zh) | 2018-03-05 | 2021-02-26 | 奥克梅斯制药爱尔兰有限公司 | 阿立哌唑的给药策略 |
WO2024091523A1 (en) * | 2022-10-24 | 2024-05-02 | 2A Biosciences, Inc. | Conformationally restricted phenethylamine analogs |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4366172A (en) * | 1977-09-29 | 1982-12-28 | The Upjohn Company | 4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use |
JPH0625181B2 (ja) * | 1985-03-27 | 1994-04-06 | 住友製薬株式会社 | 新規なイミド誘導体 |
US5219879A (en) * | 1990-03-05 | 1993-06-15 | Du Pont Merck Pharmaceutical Company | Heterocyclic steroid compounds |
JP2800953B2 (ja) * | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
IT1242929B (it) * | 1990-11-07 | 1994-05-18 | Nordica Spa | Struttura di leva per calzature sportive, particolarmente per scarponi da sci |
JP3948744B2 (ja) * | 1994-11-04 | 2007-07-25 | 大日本住友製薬株式会社 | 新規なラクタム誘導体 |
JP3775823B2 (ja) * | 1995-06-09 | 2006-05-17 | 大日本住友製薬株式会社 | 新規なイミド誘導体 |
AU3789901A (en) * | 1999-12-17 | 2001-06-25 | Bristol-Myers Squibb Company | Antipsychotic heterocycle compounds |
US6599901B1 (en) * | 2001-11-19 | 2003-07-29 | Hoffman-La Roche Inc. | Pyridone substituted benzothiazole derivatives |
EP1637530A4 (en) | 2003-06-23 | 2009-04-01 | Dainippon Sumitomo Pharma Co | THERAPEUTIC AGENT FOR SENILE DEMENTIA |
ATE543817T1 (de) | 2003-07-29 | 2012-02-15 | Dainippon Sumitomo Pharma Co | Verfahren zur herstellung einer imidverbindung |
EP1726952A4 (en) | 2004-02-20 | 2008-06-18 | Dainippon Sumitomo Pharma Co | METHOD FOR IN VIVO SCREENING OF A THERAPEUTIC FOR A MEMORY / LEARNING FUNCTION THROUGH SCHIZOPHRENIA |
ES2398312T3 (es) | 2007-04-04 | 2013-03-15 | Merck Sharp & Dohme Corp. | Agentes terapéuticos |
US20090076027A1 (en) | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched lurasidone |
US20110003994A1 (en) | 2009-07-02 | 2011-01-06 | Dainippon Sumitomo Pharma Co., Ltd. | Cycloalkane derivative |
-
2008
- 2008-04-03 ES ES08742520T patent/ES2398312T3/es active Active
- 2008-04-03 KR KR1020097020674A patent/KR101562835B1/ko active IP Right Grant
- 2008-04-03 JP JP2010502133A patent/JP5097265B2/ja not_active Expired - Fee Related
- 2008-04-03 EP EP08742520A patent/EP2144905B1/en active Active
- 2008-04-03 DK DK08742520.3T patent/DK2144905T3/da active
- 2008-04-03 PT PT87425203T patent/PT2144905E/pt unknown
- 2008-04-03 NZ NZ580167A patent/NZ580167A/en not_active IP Right Cessation
- 2008-04-03 RU RU2009136592/04A patent/RU2468025C2/ru not_active IP Right Cessation
- 2008-04-03 CA CA2682494A patent/CA2682494C/en not_active Expired - Fee Related
- 2008-04-03 MY MYPI20094078A patent/MY153868A/en unknown
- 2008-04-03 MX MX2009010678A patent/MX2009010678A/es active IP Right Grant
- 2008-04-03 WO PCT/US2008/004336 patent/WO2008124030A1/en active Application Filing
- 2008-04-03 SI SI200830896T patent/SI2144905T1/sl unknown
- 2008-04-03 PL PL08742520T patent/PL2144905T3/pl unknown
- 2008-04-03 US US12/530,944 patent/US8252799B2/en active Active
- 2008-04-03 BR BRPI0809492-6A patent/BRPI0809492A2/pt not_active Application Discontinuation
- 2008-04-03 CN CN2008800146754A patent/CN101675046B/zh not_active Expired - Fee Related
- 2008-04-03 UA UAA200910034A patent/UA96015C2/ru unknown
- 2008-04-03 AU AU2008236705A patent/AU2008236705B2/en not_active Ceased
- 2008-04-03 RS RS20130023A patent/RS52661B/en unknown
-
2009
- 2009-09-18 ZA ZA2009/06525A patent/ZA200906525B/en unknown
- 2009-09-25 NI NI200900175A patent/NI200900175A/es unknown
- 2009-09-29 GT GT200900258A patent/GT200900258A/es unknown
- 2009-09-29 SV SV2009003380A patent/SV2009003380A/es unknown
- 2009-09-29 IL IL201235A patent/IL201235A/en not_active IP Right Cessation
- 2009-09-30 CR CR11047A patent/CR11047A/es unknown
- 2009-10-01 CO CO09107560A patent/CO6300938A2/es active IP Right Grant
- 2009-10-02 EC EC2009009674A patent/ECSP099674A/es unknown
- 2009-10-02 DO DO2009000232A patent/DOP2009000232A/es unknown
- 2009-10-21 MA MA32295A patent/MA31323B1/fr unknown
-
2010
- 2010-02-18 HK HK10101754.2A patent/HK1134291A1/xx not_active IP Right Cessation
-
2012
- 2012-08-21 US US13/590,210 patent/US8410111B2/en not_active Expired - Fee Related
- 2012-09-20 JP JP2012207291A patent/JP5686780B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-17 HR HRP20130041AT patent/HRP20130041T8/hr unknown
- 2013-02-08 CY CY20131100117T patent/CY1113649T1/el unknown
- 2013-03-04 US US13/783,772 patent/US9867821B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2009000232A (es) | Metanoisoindoles y dionas de éstos como agentes anti-psicóticos. | |
MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
UY32547A (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
PE20160844A1 (es) | Compuestos triciclicos como agentes anticancerigenos | |
NI201200089A (es) | INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA. | |
CR11150A (es) | Compuestos de bencimidazol | |
MX2019015237A (es) | Combinaciones que comprenden brexpiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central. | |
BR112015032637A2 (pt) | derivados de pirrolopiridina ou pirazolopiridina | |
EA201100161A1 (ru) | Производные хинуклидина карбоната и их медицинские композиции | |
GT200600422A (es) | Derivados de carboxamida como antagonistas del receptor muscarinico | |
PE20121556A1 (es) | 3,6-diazabiciclo[3.1.1]heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina | |
EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
PH12016502251A1 (en) | Peptides as oxytocin agonists | |
MX352548B (es) | Compuestos disustituidos de tetrahidrofuranilo como antagonistas de receptor de bradiquinina b1. | |
ECSP11011415A (es) | Piperidinas sustituidas como antagonistas de ccr3. | |
CR20160142A (es) | Pirido [4,3-b]pirazín-2-carboxamidas como agentes neurogénicos para el tratamiento de trastornos neurodegenerativos | |
BRPI0808828A2 (pt) | compostos de dibenzo[b,f][1,4]oxazapina | |
AR075196A1 (es) | Un derivado de cianopirimidina para el tratamiento de una enfermedad ocular | |
UY30908A1 (es) | Derivados de azabicicloalcano, su preparacion y su aplicacion en terapeutica | |
AR071096A1 (es) | Derivados de la 2-trifluorometilnicotinamida como agentes para aumentar el hdl-colesterol | |
UY32448A (es) | Derivados de 3-benzofuranil-indol-2-ona-3-acetamidopiperazinas sustituidos, su preparacion y su aplicacion en terapeutica | |
UY32447A (es) | Derivados de 3-benzofuranilindol-2-ona sustituidos en 3, su preparacion y su aplicacion en terapia | |
CO6511224A2 (es) | Utilización de derivados del indol como activadores de nurr-1 para la aplicación de tratamientos de enfermedades como el parkison | |
HN2009002018A (es) | Compuestos de hexahidro-1 h-4,7-metano isoindol-1,3-diona | |
AR073711A1 (es) | Derivados de isoquinolina |